FluidAI Medical, a Canadian medical technology company specialising in artificial intelligence and sensor-based healthcare solutions, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Origin™ device — a key step in advancing data-driven post-operative care.
Origin™ is an inline sensing system designed to provide real-time, bedside monitoring of surgical effluent in patients recovering from surgery.
The device connects to standard surgical drains and delivers continuous pH data visualisation, giving clinical teams immediate insight into post-operative biochemical changes.
It can function as a standalone unit or integrate with FluidAI’s Stream Care™ platform, an AI-assisted surgical support system.
The FDA clearance marks an important milestone for FluidAI as it aims to enhance recovery monitoring and expand its market presence.
The company believes the technology will enable clinicians to detect early biochemical indicators of recovery or potential complications, moving postoperative care from a reactive to a proactive model.
The device also contributes to developing smarter and more personalised healthcare algorithms by providing access to continuous drainage data, a typically underused clinical resource.
FluidAI expects this approach to support faster recovery times, fewer hospital readmissions, and improved patient outcomes.
